LIVZON PHARMA (01513): Received Drug Clinical Trial Approval Notice for Injectable Brivaracetam Microspheres

LIVZON PHARMA (01513) announced that its wholly-owned subsidiary, Zhuhai Lijie Microsphere Technology Co., Ltd., has received the "Drug Clinical Trial Approval Notice" (Notice number: 2026LP00935) issued by the National Medical Products Administration, approving the company's application for conducting clinical trials of injectable brexpiprazole microspheres for the treatment of adult schizophrenia. The injectable brexpiprazole microspheres are a sustained-release microsphere formulation independently developed by the company, representing a new generation of antipsychotic medication for schizophrenia. This product works through partial agonism of dopamine D2, 5-HT1A receptors, and synergistic antagonism of receptors such as norepinephrine, showing superior performance in various safety indicators compared to other medications of the same generation. Designed for long-acting sustained release, this product is intended for monthly intramuscular injections, which can improve patient medication compliance, reduce the risk of relapse, and address clinical challenges such as low treatment compliance and high relapse rates in schizophrenia patients, meeting the long-term maintenance treatment needs in clinical practice. Currently, oral formulations of brexpiprazole have been approved for multiple indications of psychiatric disorders worldwide, but there is no long-acting formulation of brexpiprazole approved for marketing. This product represents an improved new drug development to fill this clinical gap.